Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing

Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close to RMB 100 million (USD 13.96 million) in a Pre-Series B financing round. Investors included Chengdu Bio City No. 1 Equity Investment Fund, Chengdu Gaoxin New Economy Venture Capital, Pengzhou Global Biomedical Technology Achievement Transformation Equity Investment Fund, Chengdu Gaotou Biomedical Park Management, CDHT Venture Capital Co., Ltd, and Shenzhen Jiuyuan Changqing Equity Investment Fund. The proceeds will be used to support an Investigational New Drug (IND) filing and a Phase I clinical study for its first antibody-drug conjugate (ADC) SMP-656, ADC technology platform construction, and regulatory filing and commercial layout for generic drugs with high technology barriers in China and beyond.

Company Profile and Pipeline
Founded in 2016, Xiling Lab aims to develop a world-leading small molecule innovative drug research and development platform, contrast agent drug development platform, catalytic technology platform, and ADC technology platform. The company boasts a “Linker + Drug” molecule bank based on its conjugate drug platform XL-XDC. Its lead ADC product has yielded excellent pre-clinical data, positioning the company for significant advancements in the field of oncology and drug delivery.

Future Plans
With the new funding, Xiling Lab plans to accelerate its IND filing and Phase I clinical study for SMP-656, enhance its ADC technology platform, and expand its regulatory and commercial presence for high-barrier generic drugs both in China and internationally. This strategic move will help the company further solidify its position in the global pharmaceutical market and drive innovation in drug development.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry